Wellstat grants rights for use of uridine triacetate as an antidote to overexposure to the chemotherapy drug 5-fluorouracil (5-FU) due to dosing errors or impaired clearance of 5-FU from the body.
Under the agreement Wellstat will be responsible for development and regulatory filings and for product manufacture, and in return it will receive an upfront payment, a payment upon option exercise, and transfer pricing payments based on manufacturing costs and a significant percentage of net sales from BTG.
Wellstat Licensing and Business Development vice president David Wohlstadter said expanding the company’s relationship with BTG will increase medical awareness of 5-FU overexposure, and help supply uridine triacetate on a Named Patient basis in the EU.
"In entering into this new agreement, BTG further demonstrated its commitment to addressing patient needs in oncology and antidote therapies. We look forward to further development and commercialization of uridine triacetate in territories outside the U.S. and E.U. as well as in other indications worldwide," Wohlstadter added.
Previously, Wellstat granted BTG US marketing rights to uridine triacetate for the treatment of 5-FU overexposure, while retaining commercialization rights for this indication and for all other potential uses of uridine triacetate outside of the US and EU.